Small molecules showing significant protection of mice against botulinum neurotoxin serotype a

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Pang, Yuan Ping ^a   Davis, Jon ^b,c   Wang, Shaohua ^a   Park, Jewn Giew ^a   Nambiar, Madhusoodana P ^b   Schmidt, James J ^c   Millard, Charles B ^b,d  

^a MAYO CLINIC   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A ENDOPEPTIDASE INHIBITOR; F3A; F4H; H3H; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; NEUROTOXIN; PROTECTIVE AGENT; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; BOTULISM; CELL PROTECTION; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; SURVIVAL RATE; ANIMAL; BIOLOGICAL WARFARE; COST; DRUG ANTAGONISM; ECONOMICS;

MAMMALIA; MUS;

ANIMALS; BIOTERRORISM; BOTULINUM TOXINS, TYPE A; COSTS AND COST ANALYSIS; MICE; NEUROTOXINS; PROTEASE INHIBITORS; PROTECTIVE AGENTS; SURVIVAL RATE;

EID: 77956316779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010129     Document Type: Article

References (45)

1. Shapiro RL, Hatheway C, Swerdlow DL (1998) Botulism in the United States - a clinical and epidemiologic review. Ann Intern Med 129: 221-228.
2. Kessler KR, Benecke R (1997) Botulinum toxin-from poison to remedy. Neurotoxicology 18: 761-770.
3. Springen K, Raymond J, Skipp C, Scelfo J, SS (2002) The Botox boom. Newsweek. pp 50-58.
4. Crowner BE, Brunstrom JE, Racette BA (2007) Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 30: 310-313.
5. Kuehn BM (2009) FDA requires black box warnings on labeling for botulinum toxin products. JAMA 301: 2316.
6. Liang BA (2006) Fade to black: importation and counterfeit drugs. Am J Law Med 32: 279-323.
7. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, et al. (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278: 1363-1371.
8. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285: 1059-1070.
9. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, et al. (1997) Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278: 399-411.
10. Wein LM, Liu Y (2005) Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci USA 102: 9984-9989.
11. Arnon SS (2007) Creation and development of the public service orphan drugv Human Botulism Immune Globulin. Pediatrics 119: 785-789.
12. Larsen JC (2009) U.S. Army botulinum neurotoxin (BoNT) medical therapeutics research program: past accomplishments and future directions. Drug Develop Res 70: 266-278.
13. Boldt GE, Eubanks LM, Janda KD (2006) Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb). pp 3063-3065.
14. Tang J, Park JG, Millard CB, Schmidt JJ, Pang Y-P (2007) Computer-aided lead optimization: improved small-molecule inhibitor of the zinc endopeptidase of botulinum neurotoxin serotype A. PLoS ONE 2: e761.
15. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, et al. (2007) Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 282: 5004-5014.
16. Johnson SL, Chen LH, Harbach R, Sabet M, Savinov A, et al. (2008) Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem Biol Drug Des 71: 131-139.
17. Moe ST, Thompson AB, Smith GM, Fredenburg RA, Stein RL, et al. (2009) Botulinum neurotoxin serotype A inhibitors: Small-molecule mercaptoacetamide analogs. Bioorg Med Chem 17: 3072-3079.
18. Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, et al. (2009) Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Ch 53: 3478-3486.
19. Pang Y-P, Vummenthala A, Mishra RK, Park JG, Wang SH, et al. (2009) Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. PLoS ONE 4: e7730.
20. Cai S, Lindo P, Park JB, Vasa K, Singh BR (2010) The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity. Toxicon 55: 818-826.
21. Simpson LL (1981) The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33: 155-188.
22. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. (2007) An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 104: 2602-2607.
23. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, et al. (2006) Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem 14: 395-408.
24. Muller K, Faeh C, Diederich F (2007) Fluorine in pharmaceuticals: looking beyond intuition. Science 317: 1881-1886.
25. Schmidt JJ, Bostian KA (1997) Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem 16: 19-26.
26. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE, Jr. (1984) Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 150: 407-412.
27. Sarvas H, Seppala I, Kurikka S, Siegberg R, Makela O (1993) Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 13: 145-151.
28. Schmidt JJ, Stafford RG, Bostian KA (1998) Type A botulinum neurotoxin proteolytic activity - development of competitive inhibitors and implications for substrate specificity at the s-1' binding subsite. FEBS Lett 435: 61-64.
29. Cieplak P, Cornell WD, Bayly C, Kollman PA (1995) Application of the multimolecule and multiconformational resp methodology to biopolymers: charge derivation for DNA, RNA, and proteins. J Comput Chem 16: 1357-1377.
30. Frisch MJ, Trucks GW, Schlegel HB, Gill PMW, Johnson BG, et al. (1999) GAUSSIAN 98, Revision A.7. Gaussian, Inc Pittsburgh, PA.
31. Pang Y-P (1999) Novel zinc protein molecular dynamics simulations: steps toward antiangiogenesis for cancer treatment. J Mol Model 5: 196-202.
32. Pang Y-P, Xu K, El Yazal J, Prendergast FG (2000) Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. Protein Sci 9: 1857-1865.
33. Pang Y-P (2001) Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in phosphotriesterase using the cationic dummy atom method. Proteins 45: 183-189.
34. Silvaggi NR, Wilson D, Tzipori S, Allen KN (2008) Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 47: 5736-5745.
35. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432: 925-929.
36. El Yazal J, Pang Y-P (1999) Ab initio calculations of proton dissociation energies of zinc ligands: hypothesis of imidazolate as zinc ligand in proteins. J Phys Chem B 103: 8773-8779.
37. El Yazal J, Roe RR, Pang Y-P (2000) Zinc's affect on proton transfer between imidazole and acetate predicted by ab initio calculations. J Phys Chem B 104: 6662-6667.
38. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE III, et al. (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 91: 1-41.
39. Jorgensen WL, Chandreskhar J, Madura JD, Impey RW, Klein ML (1982) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
40. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The Amber biomolecular simulation programs. J Comput Chem 26: 1668-1688.
41. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
42. Wickstrom L, Okur A, Simmerling C (2009) Evaluating the performance of the ff99SB force field based on NMR scalar coupling data. Biophys J 97: 853-856.
43. Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81: 3684-3690.
44. Darden TA, York DM, Pedersen LG (1993) Particle Mesh Ewald: An N log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
45. Shao J, Tanner SW, Thompson N, Cheatham TE, III (2007) Clustering molecular dynamics trajectories: 1. characterizing the performance of different clustering algorithms. J Chem Theory Comput 3: 2312-2334.